LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Search

Roivant Sciences Ltd

Cerrado

SectorSanidad

28.81 3.52

Resumen

Variación precio

24h

Actual

Mínimo

27.83

Máximo

28.84

Métricas clave

By Trading Economics

Ingresos

-200M

-314M

Ventas

428K

2M

Margen de beneficios

-15,692.896

Empleados

750

EBITDA

-132M

-290M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+22.36% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

5B

20B

Apertura anterior

25.29

Cierre anterior

28.81

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 may 2026, 23:41 UTC

Ganancias

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 may 2026, 21:40 UTC

Ganancias

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 may 2026, 23:34 UTC

Charlas de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 may 2026, 23:12 UTC

Ganancias

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 may 2026, 23:11 UTC

Ganancias

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 may 2026, 23:07 UTC

Ganancias

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 may 2026, 23:05 UTC

Ganancias

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 may 2026, 23:04 UTC

Ganancias

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 may 2026, 22:50 UTC

Ganancias

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 may 2026, 22:25 UTC

Charlas de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 may 2026, 22:05 UTC

Charlas de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 may 2026, 21:58 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:47 UTC

Charlas de Mercado
Ganancias

Costco Posts 13% Sales Growth in April -- Market Talk

6 may 2026, 21:46 UTC

Ganancias

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 may 2026, 21:40 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:35 UTC

Charlas de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 may 2026, 21:32 UTC

Acciones populares

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 may 2026, 21:29 UTC

Ganancias

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

22.36% repunte

Estimación a 12 Meses

Media 34.7 USD  22.36%

Máximo 41 USD

Mínimo 29 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat